See more : The Brooker Group Public Company Limited (BTC.BK) Income Statement Analysis – Financial Results
Complete financial analysis of COMPASS Pathways plc (CMPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of COMPASS Pathways plc, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- Cogeco Inc. (CGO.TO) Income Statement Analysis – Financial Results
- Energy Action Limited (EAX.AX) Income Statement Analysis – Financial Results
- Light & Wonder, Inc. (LNW) Income Statement Analysis – Financial Results
- Aeon Hokkaido Corporation (7512.T) Income Statement Analysis – Financial Results
- Toubujyuhan Co.,Ltd. (3297.T) Income Statement Analysis – Financial Results
COMPASS Pathways plc (CMPS)
About COMPASS Pathways plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 0.00 |
Gross Profit | -242.94K | -329.80K | -174.98K | -112.00K | -63.00K | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 87.52M | 65.05M | 44.03M | 23.37M | 12.56M | 8.92M |
General & Administrative | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
Other Expenses | 0.00 | -14.42M | -9.65M | -4.25M | -2.73M | -2.68M |
Operating Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
Cost & Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
Interest Income | 0.00 | 0.00 | 40.00 | 319.00 | 73.00 | 0.00 |
Interest Expense | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 22.00K |
EBITDA | -123.80M | -110.40M | -83.22M | -47.04M | -18.39M | -10.52M |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -136.92M | -110.40M | -83.22M | -51.39M | -21.18M | -12.50M |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 19.24M | 19.31M | 11.68M | -8.91M | 1.58M | -716.00K |
Income Before Tax | -117.68M | -91.10M | -71.54M | -60.30M | -19.60M | -13.22M |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 780.00K | 408.00K | 199.00K | 32.00K | 15.00K | -716.00K |
Net Income | -118.46M | -91.51M | -71.74M | -60.33M | -19.61M | -13.22M |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
EPS Diluted | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
Weighted Avg Shares Out | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
Weighted Avg Shares Out (Dil) | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
Cubic Awarded U.S. Air Force Contract for Halo™-Enabled Resilient Mesh (HERMes) System
COMPASS Pathways earns repeat ‘Buy' rating and US$60 price target on adjusted trial design for COMP360
2 Growth Stocks With Incredible Potential in the Next 5 Years
COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference
COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023
3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street
7 Tempting Sin Stocks to Buy for Promising Profits
The 7 Most Promising Psychedelic Stocks to Buy in February
Psychedelic Sunday: Competitive Strategies
All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy
Source: https://incomestatements.info
Category: Stock Reports